TriSalus Life Sciences (TLSI) Research & Development (2022 - 2026)

TriSalus Life Sciences has reported Research & Development for 5 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 6.45% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (changed 0.13% YoY), and the FY2025 full-year result was $15.0 million, down 15.39% from the prior year.
• Research & Development for Q1 2026 stood at $3.2 million, up from $2.6 million in the prior quarter.
• The five-year high for Research & Development was $9.5 million in Q3 2023, with the low at $2.6 million in Q4 2025.
• Historically, Research & Development has averaged $5.1 million across 5 years, with a median of $4.8 million in 2022.
• Annual changes were most pronounced in 2023 — Research & Development jumped 97.71% — and 2024, when it tumbled 61.91%.
• TriSalus Life Sciences' Research & Development stood at $6.3 million in 2022, then increased by 23.97% to $7.8 million in 2023, then plunged by 61.91% to $3.0 million in 2024, then declined by 13.15% to $2.6 million in 2025, then advanced by 25.14% to $3.2 million in 2026.
• The last three Research & Development figures came in at $3.2 million (Q1 2026), $2.6 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.